10:50 AM EDT, 05/01/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.